"10.1371_journal.pone.0060747","plos one","2013-04-17T00:00:00Z","Erika J Lampert; Kingshuk Roy Choudhury; Christopher A Hostage; Jeffrey R Petrella; P Murali Doraiswamy; the Alzheimerâ€™s Disease Neuroimaging Initiative","Department of Psychiatry, Duke University Medical Center, Durham, North Carolina, United States of America; Department of Radiology, Duke University Medical Center, Durham, North Carolina, United States of America; The Duke Institute for Brain Sciences, Duke University Medical Center, Durham, North Carolina, United States of America","Conceived and designed the experiments: PMD KRC JRP. Performed the experiments: JRP PMD. Analyzed the data: EJL KRC PMD. Contributed reagents/materials/analysis tools: JRP CAH KRC PMD. Wrote the paper: EJL PMD CAH KRC.","The Alzheimers Disease Neuroimaging Initiative is funded by Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. PMD owns stock in Sonexa and Clarimedix, whose products are not discussed here. Jeffrey Petrella is on the neuroradiology advisory board of Janssen Alzheimer Immunotherapy. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","04","Erika J Lampert","EJL",6,TRUE,3,2,3,4,TRUE,TRUE,TRUE,1,"6",TRUE
